Marketing: Page 87
-
Deep Dive
Jilting generics: Part 1 of an exclusive interview with GPhA CEO Ralph Neas
Generic Pharmaceutical Association (GPhA) president Ralph Neas says the misuse of REMS and other restricted access programs is costing billions in potential annual savings.
By Nicole Gray • Aug. 14, 2014 -
Falling sales, Sovaldi force Vertex to ditch hep C drug
After a highly successful launch in 2011, sales of Incivek (telaprevir) for the treatment of hepatitis C have dropped in response to competitive pressure from Gilead’s Sovaldi (sofosbuvir).
By Nicole Gray • Aug. 13, 2014 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Boehringer to slash global workforce as earnings fall
The day after announcing 2014 mid-year earnings that were lower than last year's, Boehringer Ingelheim (BI) revealed plans to consolidate.
By Nicole Gray • Aug. 13, 2014 -
Boehringer sales fall, but long-term prospects look good
The first six months of 2014 were challenging for Boehringer Ingelheim (BI), but the company scored two recent FDA approvals and has a robust pipeline of almost ready-to-launch products.
By Nicole Gray • Aug. 12, 2014 -
FDA
Deep DiveDoes faster regulatory approval translate into safety problems?
Expedited reviews. Postmarketing requirements. Encouraging innovation. The FDA is trying to balance stakeholders' needs and desires while honoring the Prescription Drug User Fee Act.
By Nicole Gray • Aug. 12, 2014 -
FDA green lights J&J's 2-in-1 diabetes drug
Johnson & Johnson's Invokamet is a fixed-dose combination of Invokana (canaglifozin) and metformin.
By Nicole Gray • Aug. 12, 2014 -
Sanofi nabs rights to MannKind's inhaled insulin with $150 million deal
MannKind's Afrezza is the first insulin inhalation powder to be approved for use in the U.S. Sanofi could wind up paying the company up to $925 million for it.
By Sy Mukherjee • Aug. 11, 2014 -
Deep Dive
Another perspective on Sovaldi: Spend more now, save much more later
In an article in the NYT, Margot Sanger-Katz suggests that the up-front costs of treating hepatitis C with Sovaldi will be offset by long-term cost-savings. But her reasoning goes beyond the normal arguments.
By Nicole Gray • Aug. 8, 2014 -
Australia's drug regulator says Pradaxa safety advice will not change
Consumer health groups have requested a safety review of the drug because of deaths and adverse events.
By Nicole Gray • Aug. 6, 2014 -
Deep Dive
Prevention efforts critical as HIV stigma falls
Now that the CDC has issued HIV prevention guidelines, will use of Gilead's Truvada as a preventative medication take hold?
By Nicole Gray • Aug. 5, 2014 -
Sunshine Biopharma seeks global market through new Canadian subsidiary
Sunshine Biopharma Canada will tap into the generics market as an additional source of revenue.
By Nicole Gray • July 31, 2014 -
AZ buys rights to Almirall's respiratory portfolio in $2.1 billion deal
This deal signals AstraZeneca’s strength and independence.
By Nicole Gray • July 31, 2014 -
GSK's once-weekly diabetes injection launches in U.S. pharmacies
Tanzeum (albiglutide) was approved by the FDA in April.
By Nicole Gray • July 31, 2014 -
Montgomery County Planning Commission
Merck outperforms second-quarter expectations as earnings surge
Second-quarter earnings are up by more than 100% compared with Q2 2013.
By Nicole Gray • July 30, 2014 -
Pfizer's Q2 earnings-per-share rise despite plummeting revenues
The discrepancy is due to Pfizer's spin-off of its animal health business last year.
By Nicole Gray • July 30, 2014 -
Novartis' Simbrinza approved for glaucoma treatment in the EU
In clinical studies, Simbrinza lowered elevated intraocular pressure by as much as 37%.
By Nicole Gray • July 30, 2014 -
Generic drug use is saving UK's NHS $21 billion per year
The largest cost-savings have stemmed from more affordable versions of Lipitor.
By Nicole Gray • July 30, 2014 -
US-based Alimera Sciences gets approval to market Iluvien in Norway
The company’s strategy centers on broad penetration of the European market as well as gaining drug approvals in the US.
By Nicole Gray • July 30, 2014 -
Can GSK overcome its Q2 blues by focusing on the future?
In the face of corruption allegations and diminished earnings forecasts, GSK is looking toward the horizon.
By Nicole Gray • July 29, 2014 -
Onco360 to distribute Gilead's Zydelig
PharMerica Corporation owns a substantial portion of Onco360.
By Nicole Gray • July 28, 2014 -
Reckitt Benckiser to spin off pharmaceutical business
RB Pharmaceuticals will become a stand-alone business, with the core company focusing on consumer health and hygiene.
By Nicole Gray • July 28, 2014 -
Deep Dive
Anatomy of a drug price valuation
Is $20,000 a month too much to pay for a lifesaving therapy?
By Nicole Gray • July 27, 2014 -
Celgene's 25% profit spike driven by multiple myeloma, cancer drugs
The company’s multiple myeloma drugs performed exceptionally well, as did the cancer treatment Abraxane.
By Nicole Gray • July 25, 2014 -
Biogen Idec zips past analysts' earnings forecasts
Strong Tecfidera (dimethyl fumarate) sales led a solid performance by the company’s multiple sclerosis (MS) franchise and helped drive a 46% rise in profits.
By Nicole Gray • July 25, 2014 -
Gilead earnings soar on Sovaldi's success
The company's earnings are up 135%. Second-quarter sales of Sovaldi were close to $3.5 billion.
By Nicole Gray • July 25, 2014
Previous
